Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference
September 13, 2021 06:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading...
Relay Therapeutics Announces Corporate Updates and Reports Second Quarter 2021 Financial Results
August 12, 2021 16:05 ET
|
Relay Therapeutics, Inc.
Company selected RLY-2608 as PI3Kα mutant inhibitor development candidate and plans to initiate first-in-human study in the first half of 2022 RLY-2608 potently inhibits mutants H1047X, E542X, and...
Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights
August 05, 2021 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
June 02, 2021 06:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in fireside chats at the Goldman Sachs 42nd Annual Global Healthcare...
Relay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit
May 14, 2021 06:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit...
Relay Therapeutics Reports First Quarter 2021 Financial Results
May 13, 2021 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading...
Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D.
May 10, 2021 06:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading...
Relay Therapeutics to Participate in Fireside Chat at Bank of America 2021 Health Care Conference
May 05, 2021 06:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America 2021 Health Care Conference on...
Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O’Meara and Charles Ferté
May 03, 2021 06:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading...
Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI
April 16, 2021 06:00 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics’ leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging technologies and founders in these fields ZebiAI amplifies Relay...